Investigational drug · Phase 2
Decoy20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer).
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Decoy20"
First trial start
2023
Feb 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Decoy20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- HCC - Hepatocellular Carcinoma
- CRC (Colorectal Cancer)
- Pancreatic Adenocarcinoma
- NSCLC Non-small Cell Lung Cancer
- Squamous Cell Cancer of the Head and Neck
- UC (Urothelial Cancer)
- MSI-H Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Decoy20" as an intervention, largest first.
- Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsActive, not recruiting
Indaptus Therapeutics, IncIndustry
NCT05651022 · 120 participants (planned) · Start Feb 28, 2023 · Primary completion Jun 30, 2027
Drug: Decoy20; Tislelizumab · For: Solid Tumor, Adult; HCC - Hepatocellular Carcinoma; CRC (Colorectal Cancer) and 5 more
Sites: Los Angeles, California; Newport Beach, California; Atlanta, Georgia · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.